Please login to the form below

Triple-negative breast cancer

This page shows the latest Triple-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.

Sanofi pays $160m upfront to acquire Tidal Therapeutics

with Merck &Co’s Keytruda (pembrolizumab) in patients with high-risk melanoma and other cancer types. ... BioNTech also has a number of mRNA-based candidates in development for the treatment of a number of cancer types, including advanced melanoma,

Latest news

EMA begins accelerated review of Gilead’s Trodelvy for triple-negative breast cancer

The European Medicines Agency (EMA) has begun an accelerated review of Gilead’s Trodelvy for the treatment of advanced triple-negative breast cancer. ... The validation of our EU marketing application is an important step towards addressing the
Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance

Despite failing in NSCLC, bintrafusp alfa will continue to be evaluated in a number of additional clinical trials across a range of cancer types. ... Merck. The German pharma company also recently initiated monotherapy studies in triple-negative breast
Kite and Oxford BioTherapeutics sign oncology research pact

for the treatment of metastatic triple-negative breast cancer (mTNBC).
Boehringer spends €1.18bn to acquire NBE-Therapeutics

NBE’s lead candidate, NBE-002, is currently in phase 1 clinical studies for triple negative breast cancer and a number of additional solid tumours. ... Merk &Kollegen’s manufacturing site, which is involved in ATMP-based cancer immunology treatments.
Merck strengthens oncology pipeline with $2.75bn VelosBio deal

In October, VelosBio announced that it has initiated a phase 2 clinical trial set to investigate VLS-101 for the treatment of patients with solid tumours, including patients with triple-negative ... breast cancer (TNBC), hormone receptor-positive and/or

More from news
Approximately 5 fully matching, plus 68 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
Deal Watch January 2018

The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
Pharma deals during February 2014

awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

July 2020: diversity and inclusion in clinical trials round-up

The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Account Management: Competitive Salary Offered

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Principal Medical Writer: Varies on experience

PMHub

Add my company

Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...